MedPath

Gamaleya Research Institute Of Epidemiology And Microbiology, Health Ministry Of The Russian Federation

Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

40

Active:0
Completed:14

Trial Phases

5 Phases

Phase 1:16
Phase 2:7
Phase 3:10
+2 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (36 trials with phase data)• Click on a phase to view related trials

Phase 1
16 (44.4%)
Phase 3
10 (27.8%)
Phase 2
7 (19.4%)
Not Applicable
2 (5.6%)
Phase 4
1 (2.8%)

Clinical Study of the Safety and Pharmacokinetics of the Drug Fluorothiazinone, a Concentrate for Solution Preparation for Infusion.

Not Applicable
Not yet recruiting
Conditions
Safety and Pharmacokinetics
Interventions
Drug: ¼ of the full (target) dose (solution, 5 ml)
Drug: ½ of the full (target) dose (solution, 10 ml)
Drug: full dose (solution, 20 ml)
Drug: 1 ½ of the full (target) dose (solution, 30 ml)
Drug: 2 full doses (solution, 40 ml)
Drug: course administration of the selected dose
Other: Placebo
First Posted Date
2025-09-22
Last Posted Date
2025-09-22
Lead Sponsor
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Target Recruit Count
70
Registration Number
NCT07184606

"Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Drug B10-FC After Single Administration to Adult Patients".

Not Applicable
Not yet recruiting
Conditions
COVID-19
Interventions
Drug: 1/10 therapeutic dose
Drug: 1/2 therapeutic dose
Drug: Patients with a verified diagnosis of COVID-19
Drug: full therapeutic dose
First Posted Date
2025-09-05
Last Posted Date
2025-09-05
Lead Sponsor
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Target Recruit Count
35
Registration Number
NCT07156864

An Open Clinical Trial of the Safety and Efficacy of the Drug Fluorothiazinone, 300 Mg Tablets with the Participation of Adult Patients with Chronic Bacterial Cystitis"

Phase 3
Not yet recruiting
Conditions
P. Aeruginosa
Baumannii
Klebsiella Pneumonia
E.coli Infections
Enterococcus Faecalis Infection
Chronic Bacterial Cystitis
Interventions
Drug: Fluorothiazinone, tablets 300 mg
First Posted Date
2025-02-07
Last Posted Date
2025-02-07
Lead Sponsor
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Target Recruit Count
280
Registration Number
NCT06815549

Study of the Drug B11-FC (Botulism Treatment)

Phase 1
Not yet recruiting
Conditions
Botulism
Interventions
Other: Placebo
Drug: Botulinum neurotoxin type A
First Posted Date
2024-08-30
Last Posted Date
2024-08-30
Lead Sponsor
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Target Recruit Count
40
Registration Number
NCT06580236

The Surveillance Clinical Study of Rickettsiosis

Recruiting
Conditions
Rickettsiosis
First Posted Date
2023-12-08
Last Posted Date
2023-12-08
Lead Sponsor
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Target Recruit Count
100
Registration Number
NCT06162975
Locations
🇷🇺

Altai Republic Center for HIV prophylaxis and treatment, Gorno-Altaïsk, Altai Republic, Russian Federation

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 8
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.